Lupin is recalling 43,860 bottles of Moxifloxacin Ophthalmic solution, used to treat bacterial conjunctivitis, in the US market. The US health regulator, United States Food and Drug Administration (USFDA) has classified it as a class-III recall, which is initiated in a situation in which use of or exposure to a violative product is not likely to cause adverse health consequences.
According to USFDA, the product was distributed by five wholesalers, six drug chains, four mail order pharmacies and one mail order pharmacy or supermarket, who may have further distributed it throughout the US.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.
